Patents Represented by Attorney, Agent or Law Firm Norman J. Kruse
  • Patent number: 7148054
    Abstract: The invention provides methods employing iterative cycles of recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and/or secretion of proteins and secondary metabolites.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: December 12, 2006
    Assignee: Maxygen, Inc.
    Inventors: Stephen delCardayre, Matthew Tobin, Willem P. C. Stemmer, Jon E. Ness, Jeremy Minshull, Phillip Patten, Venkiteswatan Subramanian, Linda A. Castle, Claus M. Krebber, Steve Bass, Ying-Xin Zhang, Tony Cox, Gjalt Huisman, Ling Yuan, Joseph A. Affholter
  • Patent number: 6831158
    Abstract: Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: December 14, 2004
    Assignee: Maxygen Holdings Ltd.
    Inventors: Torben Lauesgaard Nissen, Kim Vilbour Andersen, Christian Karsten Hansen, Jan Moller Mikkelsen, Hans Thalsgaard Schambye
  • Patent number: 6806063
    Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
    Type: Grant
    Filed: February 12, 2001
    Date of Patent: October 19, 2004
    Assignees: Maxygen ApS, Maxygen Holdings Ltd.
    Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
  • Patent number: 6716631
    Abstract: The invention provides methods employing iterative cycles of recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties. Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and/or secretion of proteins and secondary metabolites.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: April 6, 2004
    Assignee: Maxygen, Inc.
    Inventors: Stephen delCardayre, Matthew Tobin, William P. C. Stemmer, Jon E. Ness, Jeremy Minshull, Phillip Patten
  • Patent number: 6703240
    Abstract: The invention provides methods for generating, identifying, and selecting polynucleotides encoding novel starch metabolizing enzymes (NSME), NSME-encoding polynucleotides, compositions of recombinant shuffled NSME protein, plant cells and microbes containing a shuffled NSME polynucleotide in expressible form, plants containing a shuffled NSME polynucleotide in expressible form, novel starch compositions produced by plants and cells, uses of such plants, cells, and starch compositions.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: March 9, 2004
    Assignee: Maxygar, Inc.
    Inventors: Willem P. C. Stemmer, Venkitswaran Subramanian, Sun Ai Raillard, Gjalt Huisman
  • Patent number: 6686515
    Abstract: Methods for evolving recombinase protein homologues and RecA/VirE2 fusion proteins which complement VirE2 deficient Agrobacterium are provided. The use of recombinase protein homologues and RecA/VirE2 fusion proteins in the context of Agrobacterium mediated transformation are provided. Methods for producing transgenic organisms by homologous recombination using evolved recombinase proteins and Agrobacterium strains which express recombinase protein homologues or RecA/VirE2 fusion proteins are provided. Transgenic cells and organisms which have integrated an exogenous DNA sequence into a predetermined site in their genome are provided.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: February 3, 2004
    Assignee: Maxygen, Inc.
    Inventors: Michael Lassner, Steven delCardayre
  • Patent number: 6653072
    Abstract: Methods are provided for the evolution of proteins of industrial and pharmaceutical interest, including methods for effecting recombination and selection. Compositions produced by these methods are also disclosed.
    Type: Grant
    Filed: June 24, 1999
    Date of Patent: November 25, 2003
    Assignee: Maxygen, Inc.
    Inventors: Phillip A. Patten, Willem P. C. Stemmer
  • Patent number: 6646110
    Abstract: The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at least one non-polypeptide moiety attached to an attachment group of the polypeptide. The attachment group may e.g., be a lysine, cysteine, aspartic acid or glutamic acid residue or a glycosylation site, and the non-polypeptide moiety may e.g., be a polymer such as polyethylene glycol or an oligosaccharide. The conjugate has one or more improved properties such as increased biological half-life and reduced side effects.
    Type: Grant
    Filed: January 10, 2001
    Date of Patent: November 11, 2003
    Assignee: Maxygen Holdings Ltd.
    Inventors: Torben Lauesgaard Nissen, Kim Vilbour Andersen, Christian Karsten Hansen, Jan Moller Mikkelsen, Hans Thalsgard Schambye
  • Patent number: 6613514
    Abstract: Methods are provided for the evolution of proteins of industrial and pharmaceutical interest, including methods for effecting recombination and selection. Compositions produced by these methods are also disclosed.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: September 2, 2003
    Assignee: Maxygen, Inc.
    Inventors: Phillip A. Patten, Willem P. C. Stemmer
  • Patent number: 6605430
    Abstract: This invention provides improved monoxygenases, dehydrogenases, and transferases that are useful for the biocatalytic synthesis of compounds such as &agr;-hydroxycarboxylic acids, and aryl- and alkyl-hydroxy compounds. The polypeptides provided herein are improved in properties such as regioselectivity, enzymatic activity, stereospecificity, and the like. Methods for obtaining recombinant polynucleotides that encode these improved polypeptides are also provided, as are organisms that express the polypeptides and are thus useful for carrying out said biocatalytic syntheses. Also provided by the invention are methods for increasing said solvent resistance of organisms that are used in the synthetic methods.
    Type: Grant
    Filed: August 12, 1999
    Date of Patent: August 12, 2003
    Assignee: Maxygen, Inc.
    Inventors: Joseph A. Affholter, S. Christopher Davis, Sergey A. Selifonov
  • Patent number: 6602986
    Abstract: A method for DNA reassembly after random fragmentation, and its application to mutagenesis of nucleic acid sequences by in vitro or in vivo recombination is described. In particular, a method for the production of nucleic acid fragments or polynucleotides encoding mutant proteins is described. The present invention also relates to a method of repeated cycles of mutagenesis, shuffling and selection which allow for the directed molecular evolution in vitro or in vivo of proteins.
    Type: Grant
    Filed: November 15, 2000
    Date of Patent: August 5, 2003
    Assignee: Maxygen, Inc.
    Inventors: Willem P. C. Stemmer, Andreas Crameri
  • Patent number: 6596539
    Abstract: The invention relates to a method and compositions for modifying a phenotype of a virus, such as viral tropism and host range, by iterative sequence recombination of variant viruses and selection of improved variants.
    Type: Grant
    Filed: October 30, 1998
    Date of Patent: July 22, 2003
    Assignee: Maxygen, Inc.
    Inventors: Willem P. C. Stemmer, Phillip Patten, Nay Wei Soong
  • Patent number: 6586182
    Abstract: Methods are provided for the evolution of proteins of industrial and pharmaceutical interest, including methods for effecting recombination and selection. Compositions produced by these methods are also disclosed.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: July 1, 2003
    Assignee: Maxygen, Inc.
    Inventors: Phillip A. Patten, Willem P. C. Stemmer
  • Patent number: 6579678
    Abstract: Methods are provided for the evolution of proteins of industrial and pharmaceutical interest, including methods for effecting recombination and selection. Compositions produced by these methods are also disclosed.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: June 17, 2003
    Assignee: Maxygen, Inc.
    Inventors: Phillip A. Patten, Willem P. C. Stemmer
  • Patent number: 6576757
    Abstract: This invention is directed to antigen library immunization, which provides methods for obtaining antigens having improved properties for therapeutic and other uses. The methods are useful for obtaining improved antigens that can induce an immune response against pathogens, cancer, and other conditions, as well as antigens that are effective in modulating allergy, inflammatory and autoimmune diseases.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: June 10, 2003
    Assignee: Maxygen, Inc.
    Inventors: Juha Punnonen, Steven H. Bass, Robert Gerald Whalen, Russell Howard, Willem P. C. Stemmer
  • Patent number: 6576467
    Abstract: A method for DNA reassembly after random fragmentation, and its application to mutagenesis of nucleic acid sequences by in vitro or in vivo recombination is described. In particular, a method for the production of nucleic acid fragments or polynucleotides encoding mutant proteins is described. The present invention also relates to a method of repeated cycles of mutagenesis, shuffling and selection which allow for the directed molecular evolution in vitro or in vivo of proteins.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: June 10, 2003
    Assignee: Maxygen, Inc.
    Inventor: Willem P. C. Stemmer
  • Patent number: 6573098
    Abstract: A method for DNA reassembly after random fragmentation, and its application to mutagenesis of nucleic acid sequences by in vitro or in vivo recombination is described. In particular, a method for the production of nucleic acid fragments or polynucleotides encoding mutant proteins is described. The present invention also relates to a method of repeated cycles of mutagenesis, shuffling and selection which allow for the directed molecular evolution in vitro or in vivo of proteins.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: June 3, 2003
    Assignee: Maxygen, Inc.
    Inventor: Willem P. C. Stemmer
  • Patent number: 6569435
    Abstract: This invention is directed to antigen library immunization, which provides methods for obtaining antigens having improved properties for therapeutic and other uses. The methods are useful for obtaining improved antigens that can induce an immune response against pathogens, cancer, and other conditions, as well as antigens that are effective in modulating allergy, inflammatory and autoimmune diseases.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: May 27, 2003
    Assignee: Maxygen, Inc.
    Inventors: Juha Punnonen, Steven H. Bass, Robert Gerald Whalen, Russell Howard, Willem P. C. Stemmer
  • Patent number: 6555660
    Abstract: The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at least one non-polypeptide moiety attached to an attachment group of the polypeptide. The attachment group may e.g. be a lysine, cysteine, aspartic acid or glutamic acid residue or a glycosylation site, and the non-polypeptide moiety may e.g. be a polymer such as polyethylene glycol or an oligosaccharide. The conjugate, which has a reduced in vitro bioactivity compared to hG-CSF, has one or more improved properties such as increased biological half-life and increased stimulation of neutrophils.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: April 29, 2003
    Assignee: Maxygen Holdings Ltd.
    Inventors: Torben Lauesgaard Nissen, Kim Vilbour Andersen, Christian Karsten Hansen, Jan Moller Mikkelsen, Hans Thalsgaard Schambye
  • Patent number: 6541011
    Abstract: This invention is directed to antigen library immunization, which provides methods for obtaining antigens having improved properties for therapeutic and other uses. The methods are useful for obtaining improved antigens that can induce an immune response against pathogens, cancer, and other conditions, as well as antigens that are effective in modulating allergy, inflammatory and autoimmune diseases.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: April 1, 2003
    Assignee: Maxygen, Inc.
    Inventors: Juha Punnonen, Steven H. Bass, Robert Gerald Whalen, Russell Howard, Willem P. C. Stemmer